Hydroxyurea (Siklos)

Small molecule

Approved / Phase 4Ribonucleotide reductaseNo featureable registry evidence
Approvedregulatory verdict

Evidence outlook

Approved: Sickle Cell Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Every registered study for this drug was reviewed, and none was selected as featured evidence for its approved use, so its Featured trials section is empty.

Also approved (1)
EU
  • Prevention of recurrent painful vaso-occlusive crises in paediatric and adult patients with symptomatic sickle-cell syndrome
Product first approved 2007EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 2 (4)
Sickle Cell Disease
NCT06578507 · Theravia
2025-01-21 – 2028-02 · Sickle Cell Disease
What this study did
NCT03806452 · Theravia
2019-05-28 – 2024-05-30 · Sickle Cell Disease
What this study did
NCT05470270 · Theravia
2022-07-08 – 2022-10-28 · Sickle Cell Disease
What this study did
Other / comorbidity
NCT02957760 · Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
2015-12 – 2017-12 · Central Retinal Vein Occlusion, Non-Ischemic
What this study did
Phase 1/2 (2)
Sickle Cell Disease
NCT07708714 · Children's Hospital Medical Center, Cincinnati
2026-05-13 – 2032-11-30 · Sickle Cell Disease, Sickle Cell Anemia in Children
What this study did
Other / comorbidity
NCT06199557 · Haukeland University Hospital
2024-05-23 – 2029-09-30 · Acute Myeloid Leukemia, Adult, Myelodysplastic Syndromes, Adult
What this study did
Phase 1 (1)
Other / comorbidity
NCT05025072 · Theravia
2021-07-30 – 2021-09-29 · Healthy Volunteers
What this study did
Phase 4 (1)
Sickle Cell Disease
NCT02522104 · Theravia
2015-09-03 – 2016-11-28 · Sickle Cell Disease, Renal Function Disorder
What this study did
Used as active comparator (4)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (2)
Other / comorbidity
NCT04116502 · University of Birmingham
2019-10-25 – 2030-04-01 · Polycythemia Vera
What this study did
NCT04617028 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2021-02-05 – 2023-10-18 · Myelofibrosis
What this study did
Phase 2 (1)
Other / comorbidity
NCT05020652 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2021-11-11 – 2023-12-26 · Moderate and High Risk Myelofibrosis
What this study did
Phase 4 (1)
Sickle Cell Disease
NCT05081349 · Assiut University
2017-01-10 – 2021-07-10 · Sickle Cell Disease
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Sickle Cell Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Hydroxyurea (Siklos): this drugApprovedSmall moleculeRibonucleotide reductasenot yet gradedNo reviewed efficacy summary in this indication
Crizanlizumab-Tmca (Adakveo)ApprovedMonoclonal antibodyP-selectinPartial signalFeatured results are non-efficacy only in this race
Exagamglogene Autotemcel (Casgevy)ApprovedGene therapy / editingBCL11A erythroid enhancer (gene editing)Weak signalNo reviewed efficacy summary in this indication
Hydroxyurea (Droxia)ApprovedSmall moleculeRibonucleotide reductasenot yet gradedNo reviewed efficacy summary in this indication
Hydroxyurea (Xromi)ApprovedSmall moleculeRibonucleotide reductaseWeak signalNo reviewed efficacy summary in this indication
L-Glutamine (Endari)ApprovedSmall moleculeAmino AcidReliable signal
NCT01179217: The Number of Occurrences of Sickle Cell Crises (48 weeks): L-glutamine 3 Number of crises (range 0 to 15) | 100% Maltodextrin 4 Number of crises (range 0 to 15)
Lovotibeglogene Autotemcel (Lyfgenia)ApprovedGene therapy / editingBeta-globin gene addition (betaA-T87Q)not yet gradedNo reviewed efficacy summary in this indication
EtavopivatPhase 3—Pyruvate kinasenot yet gradedNo reviewed efficacy summary in this indication
Mitapivat (Pyrukynd)Phase 3Small moleculePyruvate kinasenot yet gradedNo reviewed efficacy summary in this indication
Decitabine / Tetrahydrouridine (NDec)Phase 2Small moleculeDNMT1 (DNA methyltransferase 1)not yet gradedNo reviewed efficacy summary in this indication
HBI-002Phase 2Small moleculeCarbon monoxide (CO)-based gas therapeutic; oral liquid CO formulationnot yet gradedNo reviewed efficacy summary in this indication
ITU512Phase 1/2Small moleculeWIZ transcription factornot yet gradedNo reviewed efficacy summary in this indication
Nula-CelPhase 1/2Gene or cell therapy (subtype unspecified)HBB gene (sickle mutation correction)not yet gradedNo reviewed efficacy summary in this indication
Ristoglogene AutogetemcelPhase 1/2Gene therapy / editingHBG1/HBG2 promotersnot yet gradedNo reviewed efficacy summary in this indication
DISC-3405Phase 1Monoclonal antibodyTMPRSS6 (matriptase-2)not yet gradedNo reviewed efficacy summary in this indication
SCD-101Phase 1——not yet gradedNo reviewed efficacy summary in this indication
VAS-101Phase 1——not yet gradedNo reviewed efficacy summary in this indication
Iloprost (Ventavis)DiscontinuedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Renizgamglogene AutogedtemcelDiscontinuedGene or cell therapy (subtype unspecified)HBG1/HBG2 promotersnot yet gradedNo reviewed efficacy summary in this indication
Voxelotor (Oxbryta)DiscontinuedSmall moleculeHemoglobin S (HbS)Reliable signal
NCT03036813: Haemoglobin response (>1 g/dL rise at week 24): voxelotor 1500 mg 46/90, 900 mg 30/92, placebo 6/92

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Hydroxyurea (Siklos) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
February 2028 (1)
Phase 2Sickle Cell DiseaseRecruiting
Est. primary completion 2028-02 · NCT06578507 · CT.gov ↗
What to watch
2030 (1)
November 2030 (1)
Phase 1/2Sickle Cell DiseaseRecruiting
Est. primary completion 2030-11-30 · NCT07708714 · CT.gov ↗
What to watch

See the full readout calendar ↗